Magnetic resonance imaging (MRI) with magnetic resonance cholangiography (MRC) has become the radiologic standard of reference for diagnosis of primary sclerosing cholangitis (PSC). However, natural history of radiologic features of PSC is poorly known. In the current study, we aimed at analyzing the course of PSC using three-dimensional (3D) MRC and liver MRI to find predictive radiologic features of progression. PSC patients, followed up in our center, with at least two 3D MRCs performed in at least a 1-year interval, were retrospectively reviewed. We built an interpretation standard model to score precisely bile ducts and liver parenchyma features. The primary endpoint was overall radiologic course, including worsening, improvement, or stabilization. Radiologic features were analyzed by logistic regression. We reviewed 289 MRIs from 64 patients upon a mean radiologic follow-up of 4 years (range, 1-9). Radiologic features worsened in 37 patients (58%) and stabilized in 27 (42%); no patient showed improvement. Multivariate analysis resulted in two MRI progression risk scores, based on the combination of predictive radiologic features (score without gadolinium administration 5 1 3 dilatation of intrahepatic bile ducts 1 2 3 dysmorphy 1 1 3 portal hypertension; score with gadolinium administration 5 1 3 dysmorphy 1 1 3 parenchymal enhancement heterogeneity). These scores were associated with radiologic progression, with an area under the curve of 80 and 83% 6 4%. Conclusion: A majority of PSC patients develop radiologic aggravation upon MRI over 4 years. Two simple scores can predict radiologic progression. (HEPATOLOGY 2014;59:242-250)
The use of cross-sectional imaging techniques for the noninvasive evaluation of small-bowel disorders is increasing. The effectiveness of magnetic resonance (MR) enterography for the evaluation of Crohn disease, in particular, is well described in the literature. In addition, MR enterography has an evolving though less well documented role to play in the evaluation of other small-bowel diseases, including various benign and malignant neoplasms arising in isolation or in polyposis syndromes such as Peutz-Jeghers, inflammatory conditions such as vasculitis and treatment-induced enteritis, infectious processes, celiac disease, diverticular disease, systemic sclerosis, and bowel duplication. MR enterography may be useful also for the evaluation of intermittent and low-grade small-bowel obstructions. Advantages of MR imaging over computed tomography (CT) for enterographic evaluations include superb contrast resolution, lack of associated exposure to ionizing radiation, ability to acquire multiplanar primary image datasets, ability to acquire sequential image series over a long acquisition time, multiphasic imaging capability, and use of intravenous contrast media with better safety profiles. MR enterography also allows dynamic evaluations of small-bowel peristalsis and distensibility of areas of luminal narrowing and intraluminal masses by repeating sequences at different intervals after administering an additional amount of the oral contrast medium. Limitations of MR enterography in comparison with CT include higher cost, less availability, more variable image quality, and lower spatial resolution. The advantages and disadvantages of MR enterography performed with ingestion of the oral contrast medium relative to MR enteroclysis performed with infusion of the oral contrast medium through a nasoenteric tube are less certain.
There are many limitations to the examination of the bile ducts by magnetic resonance imaging, which may be four orders: (1) technical, requiring analysis of Maximum Intensity Projection (MIP) three-dimensional (3D) volume reconstructions as well as native images, the use of T1-weighted sequences obtained in 3D to avoid entry slice phenomena, and knowledge of the inherent limits of the method, the spatial resolution of which is still less than optimal; (2) anatomical: you need to know the appearance of flow artefacts within the bile ducts and the traps that the presence of air or bleeding into the bile ducts can create; you also need to know the characteristic appearance of the indentation caused by the hepatic artery on the bile ducts and the variants and modifications seen in cases of portal biliopathy; (3) semiological: the terms used to describe bile duct abnormalities seen in MRI are often derived from imprecise descriptions used in retrograde cholangiography: irregularities of the bile ducts, a beaded 'string of pearls' appearance, a 'dead tree' appearance; (4) related to a complex disease, cholangitis which is a complex pathological condition, with possible overlaps between different conditions, such as primary sclerosing cholangitis (PSC), secondary sclerosing cholangitis, autoimmune cholangitis. In any case, the diagnosis of cholangiocarcinoma associated with PSC is always difficult. These limitations can be circumvented by using a precise exploration technique comprised of 3D magnetic resonance cholangiography sequences, which allow volume analysis, examination of native slices and of thick or thin MIP reconstructions, and heavily T2-weighted and T1-weighted 3D sequences with and without gadolinium injection, which is not always essential. The examination must be interpreted according to a stereotyped plan that includes (1) examination of the bile ducts, searching for and describing any stenosis, the presence or absence of dilatation, (2) a systematic search for any intrahepatic calculus, (3) examination of the heterogeneity of the liver parenchyma, investigation to find any liver dysmorphia and signs of portal hypertension, (4) analysis of the enhancement of the liver parenchyma and any enhancement of the wall of the bile ducts.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations鈥揷itations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright 漏 2025 scite LLC. All rights reserved.
Made with 馃挋 for researchers
Part of the Research Solutions Family.